0001980845 us-gaap:CommonStockMember 2026-06-16 2026-06-16 0001980845 2026-06-16 2026-06-16 0001980845 us-gaap:WarrantMember 2026-06-16 2026-06-16 0001980845 true 00-0000000 8-K/A 2026-06-16 enGene Therapeutics Inc. A1 001-41854 4868 Rue Levy, Suite 220 Saint-Laurent QC CA H4R 2P1 514 332-4888 Not Applicable false false false false Common Shares ENGN NASDAQ Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Common Share ENGNW NASDAQ true true This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by enGene Therapeutics Inc. (the "Company") with the U.S. Securities and Exchange Commission (the "SEC") on June 15, 2026 (the "Original Form 8-K") and is being filed to amend and supplement the Company's disclosure as set forth below. The information reported in the Original Form 8-K remains otherwise unchanged.